Viome PRO introduces blood test for pancreatic cancer

Viome Life Sciences’ clinical division Viome PRO has launched CancerDetect Pancreatic, a physician-ordered blood test designed to identify pancreatic ductal adenocarcinoma. The test is designed for adults aged 50 years and above, including higher-risk groups with specific genetic mutations. In blinded validation testing, the test achieved 90% specificity while detecting 86% of stage I and II cancers. Credit: Viome/PRNewswire. Viome Life Sciences’ clinical division Viome PRO has launched CancerDetect Pancreatic, a physician-ordered blood test designed to identify pancreatic ductal adenocarcinoma. The assay assesses the enzymatic activity tumours to break down surrounding tissue. Combine business intelligence and editorial excellence to reach…

Source: Medical Device Network